AM Press ReleasesMedical AMPersonalized MedicineRegenerative Medicine

BellaSeno reports positive clinical trials in breast scaffold patients

First-ever breast implant trial using PCL scaffolds and fat transfer confirms favorable safety profile

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Ten breast scaffold patients and 5 pectus patients using BellaSeno’s 3D printed resorbable implants have successfully passed one-year follow-up in Australian clinical trials. BellaSeno is an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies.

BellaSeno reports positive clinical trials in breast scaffold patients on first-ever breast implant using PCL scaffolds and fat transfer In the first-ever breast implant trial using PCL scaffolds and fat transfer, the interim analysis confirms a favorable safety profile of the Company´s resorbable soft tissue implants. No major complications such as capsular contracture, calcifications, oil cysts, infections, tissue necrosis, or wound healing issues were observed. No scaffold removals or replacements were necessary, and no scaffold-related complications were observed in any patients six months post-surgery.

“Following this favorable interim analysis, we are now well positioned to begin our pivotal clinical study to obtain full regulatory approval of our breast scaffolds in Europe and the U.S.,” said Mohit Chhaya, CEO of BellaSeno. “We are excited that our resorbable scaffolds do not only meet the desired safety criteria but have also shown an improvement in patients’ quality of life.”

Data review by the Independent Data Safety Monitoring Committee confirmed that all adverse events were within the expected range of complications for removal/replacement surgeries. In general, the Clinical Investigators observed a trend towards higher patient satisfaction with breasts and quality of life associated with BellaSeno´s scaffolds compared to baseline (i.e. silicone implants). There was high acceptability and patients did not report awareness of the scaffold in situ after six to twelve months. Identical findings were made in the one-year follow-up in pectus excavatum patients.

Based on the positive data, BellaSeno plans to initiate a pivotal clinical trial to obtain regulatory approval of the breast scaffolds.

“All patients have had consistently favorable outcomes in the follow-up ranging from six months to two years. We’re excited by the progress and at the end of this year will publish the detailed one-year interim analysis for the scientific community,” said Professor Owen Ung, Primary Investigator in the clinical trial.

So far, 41 patients have been successfully operated on and received BellaSeno´s hard or soft tissue scaffolds, for a total of 5 bone scaffolds, 36 breast or pectus scaffolds.

Consumer Products AM 2024

1,346 polymer and metal AM companies and 143 end-users. Consumer products AM generated $2.6 billion in 2023. Segment expected to grow to $28 billion by 2033 at 26.8% CAGR. This new market study fro...

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services


Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.